Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: J Immunol. 2014 Nov 10;193(12):6090–6102. doi: 10.4049/jimmunol.1401605

Figure 8. TRAM-dependent pathogen-induced type I IFN.

Figure 8

(A) WT or TRAM-deficient iBMDMs were left untreated (UT) or infected with herpes viruses HSV-1 (MOI of 3), HSV-2 (MOI of 3), MHV68 (MOI of 50), or with SeV (MOI of 0.001), or transfected with lipofectamine (Lipo) alone or with 1 μg of dsDNA, all for 10 h. Supernatants were harvested and the amount of type I IFN produced was determined by bioassay. (B) WT or TRAM-deficient iBMDMs were left untreated (Control), stimulated with Pam3CSK4 or Malp2, or infected with S. aureus strain SH1000 at MOIs of 10 and 100 for the indicated times. Supernatants were harvested and IFN-β production measured by ELISA. The data are mean ± SD of triplicate samples and are representative of two independent experiments. **p<0.005 or ***p<0.0005 compared to samples from WT iBMDMs.